Complete Remission of Refractory, Ulcerated, Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma Following Brentuximab Vedotin Therapy

被引：10
|
作者：
Patsinakidis, Nikolaos [1 ]
Kreuter, Alexander [1 ]
Moritz, Rose K. C. [1 ]
Stuecker, Markus [1 ]
Moellenhoff, Katrin [1 ]
机构：
[1] Ruhr Univ Bochum, Dept Dermatol Venereol & Allergol, DE-44791 Bochum, Germany
来源：
ACTA DERMATO-VENEREOLOGICA | 2015年 / 95卷 / 02期
关键词：
LYMPHOPROLIFERATIVE DISORDERS; EORTC; ISCL;
D O I：
10.2340/00015555-1874
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：233 / 234
页数：2
相关论文
共 50 条
  • [31] Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report
    Floyd, Erin G.
    Burns, Timothy F.
    Linos, Konstantinos
    LeBlanc, Robert E.
    Carter, Joi B.
    Jarvis, Lesley A.
    Lansigan, Frederick
    JOURNAL OF HEMATOLOGY, 2019, 8 (03) : 132 - 136
  • [32] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
  • [33] Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
    Burgstaller S.
    Thaler J.
    memo - Magazine of European Medical Oncology, 2017, 10 (3) : 170 - 172
  • [34] FingolimodPrimary cutaneous CD30+ anaplastic large-cell lymphoma: case report
    Reactions Weekly, 2019, 1737 (1) : 136 - 136
  • [35] CD30+ cutaneous lymphoproliferative disorders:: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
    Liu, HL
    Hoppe, RT
    Kohler, S
    Harvell, JD
    Reddy, S
    Kim, YH
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (06) : 1049 - 1058
  • [36] Rapid Response of locally distinct CD30 positive primary cutaneous anaplastic large T-Cell Lymphoma under Brentuximab Vedotin
    Bender-Sabelkampf, S.
    Berking, C.
    Erdmann, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 50 - 50
  • [37] Spectrum of CD30+ Lymphoid Proliferations in the Eyelid Lymphomatoid Papulosis, Cutaneous Anaplastic Large Cell Lymphoma, and Anaplastic Large Cell Lymphoma
    Sanka, R. Krishna
    Eagle, Ralph C., Jr.
    Wojno, Ted H.
    Neufeld, Kenneth R.
    Grossniklaus, Hans E.
    OPHTHALMOLOGY, 2010, 117 (02) : 343 - 351
  • [38] Brentuximab Vedotin and Ifosfamide, Carboplatin, and Etoposide (ICE) Combination Therapy for Refractory Anaplastic Large Cell Lymphoma
    Inoue, Shotaro
    Tamura, Akihiro
    Noguchi, Jun
    Nakamura, Sayaka
    Kozaki, Aiko
    Saito, Atsuro
    Ishida, Toshiaki
    Mori, Takeshi
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    PEDIATRIC BLOOD & CANCER, 2020, 67
  • [39] Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data
    Enos, Tyler H.
    Feigenbaum, Lawrence S.
    Wickless, Heather W.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1400 - 1405
  • [40] Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma
    Wolf, S.
    Goiriz, R.
    Dhairyawan, R.
    Paige, D.
    Rizvi, H.
    Haroon, A.
    Montoto, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (05) : 562 - 564
12345